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Abstract
Background: Overexpression of the transmembrane sialomucin podocalyxin, which is known to play a role in
lumen formation during polarized epithelial morphogenesis, is an independent indicator of poor prognosis in a
number of epithelial cancers, including those that arise in the breast. Therefore, we set out to determine if
podocalyxin plays a functional role in breast tumor progression.
Methods: MCF-7 breast cancer cells, which express little endogenous podocalyxin, were stably transfected with
wild type podocalyxin for forced overexpression. 4T1 mammary tumor cells, which express considerable endogenous
podocalyxin, were retrovirally transduced with a short hairpin ribonucleic acid (shRNA) targeting podocalyxin for stable
knockdown. In vitro, the effects of podocalyxin on collective cellular migration and invasion were assessed in
two-dimensional monolayer and three-dimensional basement membrane/collagen gel culture, respectively.
In vivo, local invasion was assessed after orthotopic transplantation in immunocompromised mice.
Results: Forced overexpression of podocalyxin caused cohesive clusters of epithelial MCF-7 breast tumor cells
to bud off from the primary tumor and collectively invade the stroma of the mouse mammary gland in vivo.
This budding was not associated with any obvious changes in histoarchitecture, matrix deposition or proliferation in
the primary tumour. In vitro, podocalyxin overexpression induced a collective migration of MCF-7 tumor cells
in two-dimensional (2-D) monolayer culture that was dependent on the activity of the actin scaffolding protein ezrin, a
cytoplasmic binding partner of podocalyxin. In three-dimensional (3-D) culture, podocalyxin overexpression induced a
collective budding and invasion that was dependent on actomyosin contractility. Interestingly, the collectively invasive
cell aggregates often contained expanded microlumens that were also observed in vivo. Conversely, when endogenous
podocalyxin was removed from highly metastatic, but cohesive, 4T1 mammary tumor cells there was a
decrease in collective invasion in three-dimensional culture.
Conclusions: Podocalyxin is a tumor cell-intrinsic regulator of experimental collective tumor cell invasion and
tumor budding.
Background
It is often proposed that metastatic carcinoma progres-
sion begins when single cells which have undergone an
epithelial to mesenchymal transition (EMT) break away
from the primary tumor mass and begin to invade the
surrounding tissue stroma [1]. However, when the clin-
ical tumor–stroma interface is examined in detail, the
presence and extent of small cohesive clusters of inva-
sive cells, often denoted as “tumor buds”, correlates with
metastatic progression and poor prognosis in a number
of solid tumor types [2–8], including those of the breast
[6–8]. The cells within these tumor buds, which invade
collectively, maintain at least a modicum of their original
epithelial phenotype and they often continue to form cell
junctions with their neighbors [9]. While collective
tumor cell invasion has been extensively modeled experi-
mentally [10], clinically-relevant drivers of the process
are only now beginning to be identified [11, 12].
Podocalyxin is a transmembrane sialomucin that is
normally localized to the apical surface of a variety of
epithelia, including the luminal cells of breast ducts and
lobules [13]. The physiologic function of podocalyxin
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was initially characterized in the developing kidney where
the anti-adhesive properties of the mucinous extracellular
domain act coordinately with the actin cytoskeleton-
associated cytoplasmic domain to physically separate ap-
ical membrane processes between neighboring glomerular
epithelial cells during the formation of the primary urinary
filter [14, 15]. Podocalyxin also plays a more general role
in directing the morphogenesis of tubular and glandular
epithelia by facilitating the formation of nonadhesive ap-
ical membrane domains during lumen formation [16–18].
Interestingly, Mostov and colleagues recently demon-
strated that podocalyxin can also cause normal epithelial
cells to become collectively invasive in three-dimensional
(3-D) culture when polarity cues are actively disrupted
such that apical membrane domains and lumens do
not form efficiently [19].
Podocalyxin is highly expressed in a number of human
tumors, most of which are epithelially derived, with vary-
ing degrees of prognostic significance [20–33]. In the case
of invasive breast cancer, podocalyxin overexpression is an
independent marker of poor outcome [13]. At the cellular
level, podocalyxin overexpression expands apical mem-
brane domains on the free surface of epithelial breast
cancer cells that are maintained in monolayer culture
where it alters the subcellular localization of two associ-
ated actin-binding scaffolding proteins, NHERF-1 and
ezrin [34], both of which have been implicated in breast
tumor progression when they are mistargeted [35–37].
Importantly, Casey and colleagues demonstrated that a
podocalyxin–ezrin complex increases breast tumor mo-
tility [38]. These findings, coupled with the recent ob-
servation that podocalyxin overexpression is positively
correlated with lymphovascular invasion (LVI) in breast
cancer [31], which itself is well correlated with tumor
budding [8], led us to ask whether podocalyxin over-
expression plays a functional role in collective breast
tumor cell invasion.
We found that podocalyxin overexpression caused epi-
thelial MCF-7 breast tumor cell-derived xenotransplants
to generate cohesive micronodules that budded from the
primary tumor and collectively invaded the stroma of
the mammary fat pad of immunocompromised mice. In
two-dimensional (2-D) monolayer culture, podocalyxin
overexpression induced a collective MCF-7 cell migration
that was ezrin dependent. In addition, in 3-D culture, podo-
calyxin overexpression caused cohesive MCF-7 tumor cell
clusters to expand their poorly formed internal microlu-
mens and induced a collective invasion that was dependent
on actomyosin contractility. Conversely, the stable down-
regulation of podocalyxin attenuated the collective invasion
of epithelial, but highly metastatic, 4T1 mammary tumor
cells. Therefore, podocalyxin is a clinically-relevant marker
of breast cancer progression that induces collective
tumor cell motility and invasion as well as experimental




Human MCF-7 breast cancer cells were purchased
from ATCC (Manassas, VA, USA). These cells were cohe-
sive, epithelial, and estrogen dependent for growth in vivo.
Mouse 4T1 mammary tumor cells were kindly provided
by Dr Fred Miller (Wayne State University, Detroit,
MI, USA).
Podocalyxin overexpression and downregulation
For overexpression studies, MCF-7 cells were transfected
with a pIRES2-based vector (Clonetech, Mountain View,
CA, USA) without or with the full-length murine podo-
calyxin cDNA [34]. Pooled, genetically selected, stable
cell populations were subjected to two independent rounds
of fluorescent-activated cell sorting (FACS) after indirect
immunofluorescent labeling of murine podocalyxin using
a species-specific antibody (anti-mouse PCLP-1; MBL,
Nagoya, Japan).
For downregulation studies, three different short hairpin
RNA (shRNA) sequences designed for targeted knock-
down of murine podocalyxin were identified using PSI
Oligomaker v1.5 freeware (http://web.mit.edu/jacks-lab/
protocols/pSico.html) and were cloned into the pLL3.7
lentiviral vector. Lentiviral particles were generated
after transfecting 293T cells with the pLL3.7 vector and
packaging plasmids (pVSVg, pRSV-Rev, pMDLgag/pol)
followed by transduction into subconfluent 4T1 mouse
mammary tumor cells. Infected 4T1 cells were then sub-
jected to bulk FACS for green fluorescent protein expres-
sion. Two of the resulting cell populations demonstrated
reduced podocalyxin expression, one of which was used
for functional analysis (4T1-Podo-KD 3603; see Fig. 7).
To assess steady-state protein levels, cells were lysed
in RIPA buffer (150 mM NaCl, 50 mM Tris pH 7.4,
5 mM ethylenediamine tetraacetic acid, 1.0 % NP-40,
0.5 % sodium deoxycholate, and 0.1 % sodium dodecyl
sulfate) with protease and phosphatase inhibitors. Equal
amounts of protein were then separated by SDS-PAGE,
transferred onto PVDF membranes and probed with an
anti-mouse podocalyxin primary antibody (1 μg/ml; R&D
Systems, Minneapolis, MN, USA), and primary antibodies
against E-cadherin (0.1 μg/ml; BD Biosciences, Mississauga,
ON, Canada), ZO-1 (0.25 μg/ml; Invitrogen-Zymed
Laboratories, South San Francisco, CA, USA), and epithe-
lial cytokeratins (clones AE1/AE3; Dako, Troy, MI, USA).
Primary antibody binding was visualized with the appro-
priate species-specific horseradish peroxidase-conjugated
second antibody (Jackson Immunoresearch, West Grove,
PA, USA) followed by chemoluminescence.
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Orthotopic breast tumor xenografts, quantification, and
histological analysis
17β-estradiol tablets (60-day release; IRA, Sarasota, FL,
USA) were implanted subcutaneously into the cervical
scapular space of 12-week-old female Rag 2 M mice
(Taconic, Hudson, NY, USA) and 1.0 × 106 MCF-7 cells
mixed 2:1 with Matrigel were innoculated into the right
abdominal (#4) mammary fat pad. After 6 weeks, the mice
were sacrificed and the entire mammary fat pad together
with embedded tumor material was excised. Final tumor
volumes were calculated using the formula:
Final tumor volume ¼ 0:52 length mmð Þð Þ  width mmð Þð Þ
 height mmð Þð Þ:
Approval for the xenograft study was obtained from
the Animal Care Committee of the University of British
Columbia.
Formalin-fixed and paraffin-embedded mammary glands
(control, n = 8; podocalyxin, n = 7) were serial sectioned in
their entirety. Every 10th section was deparaffinized and
stained with hematoxylin and eosin (H & E) as well as
Masson’s trichrome using standard procedures. Stained
sections were qualitatively assessed for tumor morphology,
tumor budding/collective microinvasion at tumor/stromal
borders, invasion of tumor cells into existing normal
mammary ducts, and infiltration into the surrounding
vasculature and local lymph node.
Microinvasion was quantified by counting the number
of tumor buds that extended into the stroma surround-
ing the main primary tumor. The assessed sections were
selected based on the relative location of the inguinal
lymph node (20 H & E-stained sections, each at least
50–100 μm apart, on either side of the lymph node were
analyzed; i.e., 40 total sections per tumor through an ap-
proximate tissue depth of 2–4 mm) and the average total
number of small nodules/buds and the ratio of the quan-
tity of small nodules/buds per tumor volume are shown.
Deparaffinized tissue sections were antigen-retrieved
in heated citrate buffer, blocked, and incubated with
primary antibodies against E-cadherin (0.1 μg/ml; BD
Biosciences), multiple epithelial cytokeratins using a
broad-spectrum antibody (1:200; Dako), murine podoca-
lyxin (1 μg/ml; R&D Systems), Ki67 (1:100; Abcam Inc.,
Cambridge, MA, change to: 'USA'), and ezrin (1 μg/ml; Cell
Signaling Technology Inc., Danvers, MA, USA). Antibody
binding was visualized using a horseradish peroxidase-
labeled polymer (EnVision™ + System; Dako), devel-
oped with Nova Red™ (Vector Laboratories, Burlingame,
CA, USA), and counterstained with Mayer’s hematoxylin.
2-D migration assays
Confluent MCF-7 cell monolayers were serum-starved
overnight, scratched with a p-200 micropipette tip, and
treated with 100 ng/ml epidermal growth factor (EGF)
for 16 hours. For live imaging, phase micrographs were
taken with a Nikon TMS phase Microscope equipped
with a Nikon Coolpix digital camera (Nikon, Mississauga,
ON, Canada) to capture the migratory infilling of the
scratch/wound. Wound areas were quantified using Cell-
Sens Software (Olympus, Richmond Hill, ON, Canada).
In some experiments the scratched monolayers were
treated with either dimethylsulfoxide (DMSO; vehicle
control) or the ezrin inhibitor NSC668394 (Millipore,
Etobicoke, ON, Canada [39]) diluted to 10 μM in DMSO.
3-D culture assay, quantification, and image analysis
MCF-7 cells in low serum media (Dulbecco’s modified
Eagle’s medium/F12 with 1 % fetal bovine serum) were
plated overnight onto reconstituted basement membrane
gels (Matrigel™; BD Biosciences). Spheroidal cell aggregates
were then overlaid with neutralized collagen I (2.5 mg/ml;
BD Biosciences) and maintained in low serum media sup-
plemented with EGF (100 ng/ml; Sigma, St Louis, MO,
USA) for an additional 4 days. The myosin II inhibitor
blebbistatin (10 mg/ml; Sigma) was added to the media
during extracellular matrix (ECM) overlay (day 0) and
again on day 2. On day 4 the tumor spheroids/elongating
aggregates were fixed for immunocytochemistry and con-
focal microscopic analysis as described in the next section.
To quantify spheroid/aggregate shape, the longest and
shortest axes (length and width respectively) were mea-
sured using CellSens Software (Olympus) and expressed as
an elongation index (length/width).
For time-lapse imaging, collagen I-overlaid MCF-7 cell
3-D spheroids were maintained in a stage-top incubator
(Chamlide TC™; Live Cell Instrument, Seoul, Korea), and
invasion was imaged live over a 24-hour period using a
Leica inverted DMI 4000 phase microscope equipped
with a DFC345 FX CCD camera and AF6000 imaging
software (Leica Microsystems, Concord, ON, Canada).
The 3-D culture of 4T1 cells was performed as already
described except that the cells were maintained in the
absence of serum and EGF, given that these metastatic
cells are completely growth factor-independent for
motility. Collagen I-overlaid 4T1 cultures were imaged live
for 24 hours as described, and cultures were then fixed
and immunostained for confocal analysis (described in
the following).
Immunostaining and confocal microscopy
Cultured cells were fixed in 4 % paraformaldehyde
followed by 0.25 % triton incubation. Samples were then
rehydrated in phosphate-buffered saline, blocked with
1 % bovine serum albumin/10 % normal goat serum,
and incubated with primary antibodies for 1 hour at
room temperature that included: rat anti-mouse podoca-
lyxin (1 μg/ml; R&D Systems), mouse anti-E-cadherin
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(0.25 μg/ml; BD Biosciences), rabbit anti-ZO-1 (2.5 μg/ml;
Invitrogen-Zymed Laboratories), mouse anti-cytokeratins
(clones AE1/AE3, 1:1000; Dako), rabbit anti-ezrin (1 μg/ml;
Cell Signaling Technology Inc.), and mouse anti-Muc1
(1:500; gift from Dr John Stingl, Cambridge Research
Institute, Cambridge, UK)). Cells were then incubated with
fluorescently conjugated species-specific secondary anti-
bodies (Invitrogen-Molecular Probes, Burlington, ON,
Canada), and nuclei were counterstained with 4′,6-diami-
dino-2-phenylindole (Sigma), mounted in glycerol con-
taining the anti-fade agent diazabicyclo[2.2.2]octane
(Sigma), and imaged using an Olympus FV1000 confocal
microscope (Olympus) followed by processing using
FV1000 Fluoview (Olympus) and Adobe Photoshop v12.0
software (Adobe, San Jose, CA, USA).
Results
Podocalyxin overexpression induces locally invasive
collective tumor budding in vivo
Human MCF-7 breast tumor cells are epithelial, form
well-differentiated non-invasive tumors in vivo, and ex-
press little endogenous podocalyxin [13, 38, 40]. Thus,
we generated stable MCF-7 transfectants overexpressing
mouse podocalyxin (MCF-7-podo) which can be identified
unambiguously in human cells using a species-specific
antibody [34]. MCF-7-podo cells did not exhibit a dif-
ference in steady-state levels of the epithelial markers
E-cadherin, ZO-1, or cytokeratins compared with empty
vector-transfected MCF-7-control cells (Fig. 1a). Like
the controls, MCF-7-podo cells also continued to form
E-cadherin-containing adherens junctions in both 2-D
monolayer (Fig. 3) and 3-D spheroid/aggregate (Fig. 5)
culture. Therefore, podocalyxin-overexpressing MCF-7
cells remained cohesive and epithelial.
Human MCF-7-control and MCF-7-podo cells both
formed palpable estrogen-dependent tumors after they
were orthotopically transplanted into the mammary fat
pads of immunocompromised mice. After 6 weeks there
was a trend towards slightly larger tumors in the
MCF-7-podo group that was not statistically significant
(Fig. 1b; p = 0.175; n = 8 for each condition). The same
trend towards a slight increase in tumor size in the
podocalyxin overexpression condition was also observed
in subcutaneously grown tumors (Additional file 1:
Figure S1A). Histopathologically, the central portions of
MCF-7-control and MCF-7-podo orthotopic tumors
were indistinguishable; both were characterized by densely
packed nests of cohesive tumor cells that were surrounded
by an aniline blue-positive collagenous matrix and small
areas of tissue necrosis (Fig. 1c, top panel). Furthermore,
there were no distinguishable differences in cell size
(Fig. 1c, bottom panel) or proliferation based on Ki67
staining (Fig. 1d, left panel) in the central portions of
the tumors in either condition.
While MCF-7-control tumors formed well-defined outer
borders, the outer edges of MCF-7-podo tumors were
highly irregular when observed at low power (Additional
file 1: Figure S2). Associated with the latter was a signifi-
cantly greater number of cohesive micronodules, or buds,
that surrounded the primary MCF-7-podo tumor masses
(Fig. 1c, right panel, arrows; quantified in Fig. 1e, f). While
Ki67 staining indicated an increase in proliferation at the
tumor/stromal interface compared with the tumor center
in both conditions, there was no obvious difference in Ki67
positivity in this region between the MCF-7-control and
MCF-7-podo tumors at that interface (Fig. 1d, right panels).
Through a careful analysis of serial sections we deter-
mined that some of the invasive buds located at the edge of
MCF-7-podo tumors were completely disconnected from
the primary mass (Fig. 2a, b, arrows) while others remained
connected to protrusions that emanated directly from the
primary mass (Fig. 2a, b, arrowheads). The MCF-7-podo
tumor micronodules were made up of densely-packed, co-
hesive tumor cells that, like the primary tumor, continued
to express epithelial cytokeratins (Fig. 2a) and E-cadherin
(Fig. 2b), some of which was membranous (Fig. 2b, lower
panels, higher magnification insets). In addition, these
micronodules often contained small podocalyxin-lined
microlumens (Fig. 2c, arrows). Ezrin, which is an actin scaf-
folding protein that complexes with the cytoplasmic tail of
podocalyxin [34], also lined the invasive microlumens
within the invasive nodules at the tumor/stromal interface
in the MCF-7-podo condition (Fig. 2d, right panel, arrows).
While ezrin was also localized to the plasma membrane of
tumor cells in both conditions, we observed very little evi-
dence of ezrin-lined microlumens in the MCF-7-control
condition (Fig. 2d, left panel). We concluded that podoca-
lyxin overexpression facilitates the collective budding of
invasive epithelial MCF-7 breast tumor cell micronodules
into the mammary stroma in vivo and that this is associ-
ated with microlumen formation.
Podocalyxin overexpression induces collective migration
in 2-D monolayer culture
Podocalyxin overexpression is known to increase the
serum-induced motility of individual MCF-7 cells in 2-D
monolayer culture [38]. However, when MCF-7-podo
cell monolayers were maintained at confluency they
remained cohesive and, while there was an expansion of
the apical domain, the cells continued to form E-
cadherin-containing adherens and ZO-1-containing tight
junctions and they still expressed epithelial cytokeratins
(Fig. 3a). When confluent monolayers were scratched
and stimulated with EGF, MCF-7-podo cells at the
scratch edge migrated collectively into the wound more
rapidly than did MCF-7-control cells (Fig. 3b). It is un-
likely that proliferation contributed significantly to the
increased wound filling by the MCF-7-podo cells as the
Graves et al. Breast Cancer Research  (2016) 18:11 Page 4 of 17
Fig. 1 (See legend on next page.)
Graves et al. Breast Cancer Research  (2016) 18:11 Page 5 of 17
increased collective migration was observable within the
first 16 hours after the monolayers were scratched. In
addition, there was no significant difference in the prolif-
eration of MCF-7-control and MCF-7-podo cells in
monolayer culture (Additional file 1: Figure S1B).
MCF-7-podo cells retained their E-cadherin and actin-
containing adherens junctions during collective migra-
tion (Fig. 3c, d). Interestingly, the f-actin-containing an-
terior lamellipodia were more prominent at the leading
edges of the migrating MCF-7-podo cell sheets than
were those formed by MCF-7-control cell sheets (Fig. 3b,
lower panel, note phase dark lamellipodia in the MCF-7-
podo cells at the wound edge; Fig. 3d, note increased f-
actin in the lamellipodia of MCF-7-podo cells at the
wound edge). Interestingly, podocalyxin was concen-
trated apically just behind these anterior lamellipodia
where it colocalized with a less prominent pool of
nonlamellar apical f-actin (Fig. 3d, bottom panel, z axis,
arrow). This suggests that the demonstrated ability
of podocalyxin to segregate membrane domains in
an actin cytoskeleton-dependent manner [19, 34] may play
a role in its ability to stimulate collective tumor cell
migration.
Podocalyxin interacts with the actin cytoskeleton via
ezrin which binds to its cytoplasmic domain [34] and
the separate interaction of ezrin with actin requires it to
be phosphorylated in its “ERM” domain. When we
treated MCF-7-podo cells with a pharmacological inhibi-
tor of this phosphorylation, NSC668394 [39], there was
a significant loss of the small punctate accumulations of
podocalxyin and pERM at the cell surface (Additional
file 1: Figure S3) which we have previously shown to be
associated with microvilli in the apical domain of MCF-
7-podo cell monolayers [34]. Importantly, treatment
with NSC668394 also decreased the collective migration
and the enhanced wound edge lamellipodia formation of
scratched MCF-7-podo cell monolayers (Fig. 4).
Podocalyxin overexpression induces collective epithelial
invasion and a bud-like phenotype in 3-D culture
MCF-7 cells cluster together to form non-invasive aggre-
gates when they interact with a reconstituted basement
membrane ECM (i.e., Matrigel) in 3-D culture [41].
Thus, we pre-clustered MCF-7 cell populations on Matrigel
and then overlaid them with collagen type I because we
noted an accumulation of stromal collagen in the MCF-7
cell-derived tumors that developed orthotopically within
the mammary fat pads in vivo (see Fig. 1). In addition,
other investigators have shown that the presence of stromal
collagen facilitates collective breast tumor cell invasion
[11, 12]. Under these conditions, the MCF-7-control
cell aggregates gradually increased in size over a 4-day
period. Importantly, the control cell aggregates remained
relatively spherical throughout (Fig. 5a, left panel). The lat-
ter characteristic was quantified by determining the elong-
ation index (longest length/shortest width of the cell
clusters where a perfect sphere has an index of 1.00)
which was 1.32 ± 0.04 at the end of the experiment
(Fig. 5b). In contrast, while they also started out as small
spheroidal aggregates, over the 4-day culture period many
of the MCF-7-podo cell clusters elongated and pushed out
into the matrix as cohesive multicellular extensions with
blunt-ended tips (Fig. 5a, right panel) As a result, the
mean elongation index of the MCF-7-podo cell clusters
was significantly larger than the controls (2.89 ± 0.1,
p <0.001 vs. controls; Fig. 5b). The dynamic nature
of this podocalyxin-mediated increase in collective
tumor cell invasion into the ECM was observable by live
video phase microscopy (compare Additional file 2:
Movie S1 for MCF-7-control cell clusters with Additional
file 2: Movie S2 for MCF-7-podo cell clusters).
MCF-7-control and MCF-7-podo cell clusters both
maintained their E-cadherin-containing adherens junc-
tions in 3-D culture (Fig. 5c). However, unlike nor-
mal mammary epithelial cells expressing podocalyxin
(See figure on previous page.)
Fig. 1 Podocalyxin overexpression induces collective tumor invasion in vivo. a Western blot analyses of whole cell lysates show that total
expression of E-cadherin, the tight junction protein ZO-1, and epithelial cytokeratins were unaffected by stable podocalyxin overexpression in
MCF-7-podo cells compared with MCF-7-control cells. b Podocalyxin overexpression did not significantly affect overall estrogen-dependent MCF-7
cell-derived tumor growth after orthotopic xenotransplantation (n = 8 for each condition; tumors were excised after 6 weeks; p = 0.175, two-tailed,
unpaired Student’s t test). c Representative images of trichrome-stained tumor sections (upper panels) show that MCF-7-control and MCF-7-podo
xenografts both contained densely packed tumor cells at the center of the primary tumor nodule. Both tumor types also had small areas of visible
necrosis and developed a collagenous stroma (light blue staining) that surrounded nests of cohesive tumor cells. Representative images of the
tumor/host stromal interfaces show that, compared with controls, MCF-7-podo cells more extensively protruded into the surrounding stroma at
the edge of tumor (arrowhead). These tumors also formed multiple small cohesive tumor foci, or micronodular bud-like structures (arrows), that
appeared to be separate from the primary tumor nodule (labeled P; local lymph node is labeled LN). Higher power H & E images (lower panels)
indicate that there was no a difference in tumor cell density within either the centers or edges of the lesions at the tumor/stromal interface. Scale
= 100 μm. d Tumors were immunostained with the proliferation marker Ki-67 (brown). While there was an overall increase in Ki-67-positive cells at
the tumor/stromal interface, there was no discernible difference in Ki-67 frequency between MCF-7-control and MCF-7-podo cells either at the
center of the tumors (left panel) or at the tumor/stromal interface (right panel). Scale = 100 μm. e, f The number of observable micronodules was
quantified either per tumor e or per tumor volume f. Note that, in both cases, there was a statistically significant increase in the MCF-7-podo
tumors compared with the control tumors (two-tailed, unpaired Student’s t test)
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Fig. 2 Podocalyxin overexpression induces cohesive epithelial invasion of the stroma and regional lymph node. a, b Serial sections (approximately 100 μm
apart) immunostained for cytokeratin a and E-cadherin b indicated that the stromal invasion of MCF-7-podo-derived tumor micronodules was cohesive
and epithelial. Notably, some cohesive micronodules were extensions originating from the main primary tumor (arrowheads), while others were completely
disconnected from it (arrows) a, b. Shown in the lower panels are magnified views of the outlined areas within the upper images, with further magnified
insets in the lower panels of b showing the presence of some membranous E-cadherin. Scale = 200 μm. c Representative invasive microno-
dules were serially sectioned and immunostained for epithelial cytokeratins, E-cadherin, and podocalyxin. Note that a considerable portion
of the podocalyxin localized to small microlumenal membrane surfaces within the tumor micronodules (arrows). Scale = 50 μm. d MCF-7-control and
MCF-7-podo tumor sections were immunostained for ezrin and the tumor/stromal interface was imaged. Note that while ezrin was often localized to
cell membranes in both conditions, it also lined microlumenal structures in the MCF-7-podo tumors (arrows). Scale = 50 μm
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Fig. 3 Podocalyxin stimulates collective breast tumor cell migration in 2-D monolayer culture. a Confocal XZ vertical images show that, as expected,
podocalyxin alters the architecture of the apical membrane surface of MCF-7-podo cells maintained in 2-D culture. As a result it causes the cells to
assume different shapes within the monolayers, which are much more uniform in the controls. The basolateral localization of E-cadherin is relatively
unaffected in the podocalyxin-expressing cells and tight junctions are still present apically as indicated by discrete puncta of localized ZO-1, although
the location of the latter varies within the vertical plane given the change in cell architecture. Podocalyxin does not cause a loss of epithelial keratin
filaments but it does disrupt the uniformity of their localization at the apical surface. Scale = 10 μm. b Serum-starved MCF-7-control and MCF-7-podo
cell monolayers attached to a rigid collagen I-coated substratum (0.25 μg/cm2) were subjected to a wound assay under growth factor-stimulated
conditions (EGF 100 ng/ml). The ability of the cells to close the wound after 16 hours was monitored by phase microscopy, and photomicrographs of
the same wound area after that period are shown (upper panel, 0 hours after wounding; bottom panels, 16 hours after wounding at low and high
power). There was little difference in wound closure in non-EGF-stimulated conditions (data not shown), but the podocalyxin-expressing cells were
able to close the wound more readily in response to EGF treatment compared with controls (graph, mean ± SD, unpaired Student’s t test, *p >0.05).
Data shown are from one of three representative experiments. Scale = 50 μm. c MCF-7 cells were subjected to wounding as in b and after 16 hours
they were fixed and immunostained for podocalyxin (red) and E-cadherin (green). Projections of confocal stacks at the leading edge of the wound
show that podocalyxin-expressing cells continued to form adherens junctions. Scale = 10 μm. d MCF-7 cells were subjected to wounding
as in b, and after 16 hours they were fixed and immunostained for podocalyxin (red) and f-actin (green). Projections of x/y-axis confocal
stacks show that MCF-7-podo cells have enhanced, f-actin-rich lamellipodia at their leading migratory edges compared with MCF-7-control cells (upper
three panels). X–Z-axis images (sliced along the white line shown in the x/y merged image) show that podocalyxin is polarized to the free, apical surface
membrane (arrow), but does not extend completely into the enhanced f-actin rich lamellipodia (lower panels). Scale = 10 μm
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(Additional file 1: Figure S4), MCF-7-podo cell aggregates
did not fully polarize to form a single large, central lumen.
Instead, the elongated MCF-7-podo cell clusters often
formed multiple small podocalyxin-lined microlumens
(Fig. 5c, right panel). Interestingly, the cells arranged
around some of these microlumens formed small bud-like
structures that were readily apparent when we generated
3-D reconstructions of the cell aggregates (Fig. 5c, lower
right panel, arrows).
As already noted, we previously demonstrated that
podocalyxin recruits the actin-scaffolding protein ezrin
to the free apical surface of MCF-7 cells maintained as
monolayers in 2-D culture [34]. Herein we found that
ezrin co-localized with podocalyxin around the internal
Fig. 4 The ezrin inhibitor NSC668394 decreases collective migration and leading lamellipodia formation of podocalyxin-overexpressing cells.
a Serum-starved MCF-7-control and MCF-7-podo cell monolayers were cultured and scratched as described in Fig. 3 in the presence of DMSO
(vehicle control) or the ezrin inhibitor NSC668394, and they were imaged by phase microscopy after 16 hours. Note that NSC668394 significantly
decreased the collective migration of the MCF-7-podo cells into the wound as quantified using the migration index described in Fig. 3 (mean ± SD,
unpaired Student’s t test, *p >0.05). b MCF-7-control and MCF-7-podo cells were subjected to wounding in the absence and presence of NSC668394
for 16 hours. The cells were then fixed and immunostained for podocalyxin (red) and f-actin (green). Projections of x/y confocal stacks (upper panels)
and X–Z plane images (lower panels) indicated that NSC668394 decreased the formation of f-actin-containing leading lamellipodia in the MCF-7-podo
cells. Scale = 10 μm. DMSO dimethylsulfoxide
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microlumens that formed in the collectively invasive
MCF-7-podo cell aggregates in 3-D culture (Fig. 6a,
upper panels). While the control cell clusters contained
closed internal apical membrane domains that were
marked by the mucin Muc1 (Fig. 6a, lower left panel),
podocalyxin expression caused these internal domains to
expand and open up as microlumens (Fig. 6a, lower
right panel, arrows) that preferentially recruited f-actin
Fig. 5 Podocalyxin stimulates collective breast tumor cell invasion in 3-D spheroid culture. MCF-7 cells were forced to form aggregates in 3-D
culture by first plating them overnight on Matrigel. The aggregates were then overlaid with type I collagen in the presence of EGF for the times
indicated. a The MCF-7-control cell aggregates grew considerably in size between day 1 and day 4 and remained relatively spherical. The MCF-7-podo
cell aggregates also grew in size but, in addition, they became elongated as they protruded and collectively pushed into the matrix. Live
phase microscopy; scale bar = 100 μm. b The collective invasion of the aggregates was quantified after 4 days in 3-D culture by determining
their “elongation index”, which consisted of the longest length to width ratio for each aggregate. ***p <0.001, unpaired Student’s t test. c Cell
aggregates maintained for 4 days in 3-D culture were fixed and coimmunostained for podocalyxin (red) and E-cadherin (green). Single x/y-axis
confocal images (top panels; scale = 40 μm) and 3-D reconstructed images (bottom panels) are shown. The reconstructions show that podocalyxin
promotes the cohesive elongation of the aggregates without disrupting E-cadherin localization at cell–cell adhesions. Note also that podocalyxin
primarily localized at multiple microlumina within cohesive tumor cell bud-like structures that bulged out from the elongated cell aggregates (arrows).
In the lower panels the white outlined box indicates the rotation of the reconstructed confocal stack; the long axis of each box is 211 μm in length
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Fig. 6 Podocalyxin-mediated collective invasion is actomyosin contractility dependent. a MCF-7-control and MCF-7-podo cell aggregates overlaid
with collagen were fixed and immunostained for exogenous mouse podocalyxin (red) and either the actin cytoskeletal linker ezrin (green, upper
panel) or the apical membrane marker Muc1 (green, lower panel). Single x/y-axis confocal images show that MCF-7-control cells localize ezrin to
basolateral surfaces and small membranous pockets within the spheroid interior. Apical Muc1 localized to small, closed internal domains in the
MCF-control cell aggregates. In contrast, MCF-7-podo cells predominantly localized ezrin and Muc1 to expanded microluminal surfaces within the
elongated invasive aggregates. Scale = 20 μm. b MCF-7-control and MCF-7-podo cell aggregates were fixed and stained for exogenous mouse
podocalyxin (red) and f-actin (green). Single x/y-axis confocal micrographs (top panel) and 3-D projected images (bottom panel) show an enrichment of
f-actin along the expanded microlumenal surfaces within the MCF-7-podo cell aggregates where it colocalized with podocalyxin. Also, the outer cell
surfaces of the podocalyxin aggregates exhibited prominent f-actin-rich, but podocalyxin-spare, membrane projections that probed the surrounding
ECM (arrows). Scale bar = 40 μm. c, d MCF-7 cell aggregates were maintained in the presence of either DMSO (vehicle control) or the
myosin II inhibitor blebbistatin (10 μM) for 4 days. Phase contrast images show that blebbistatin significantly blocked MCF-7-podo cells
from collectively invading the matrix by elongation c. This is quantified in d. ***p <0.001, *p <0.05, Student’s t test; scale bar = 100 μm.
DMSO dimethylsulfoxide
Graves et al. Breast Cancer Research  (2016) 18:11 Page 11 of 17
to them (Fig. 6b). Interestingly, 3-D reconstructions re-
vealed that the outer surface of MCF-7-podo cell clus-
ters, but not MCF-7-control cell clusters, often formed
f-actin-rich protrusions that were actually podocalyxin-
negative (i.e., similar to the situation in the enhanced
lamellipodia-like structures in 2-D monolayers) which
appeared to probe the surrounding collagen matrix
(Fig. 6b, bottom right panel, arrows). Very dynamic
peripheral protrusions were also observed at the edge
of the collectively invading MCF-7-podo cell aggre-
gates by live video microscopy (Additional file 2: Movie
S2). Thus, contractile actin-mediated protrusion for-
mation may contribute to the collective invasion of the
MCF-7-podo cells, a tentative conclusion that was sup-
ported by the finding that blebbistatin, a pharmaco-
logic inhibitor of actomyosin-dependent contractility,
greatly diminished their elongation/collective invasion
(Fig. 6c, d).
Podocalyxin depletion inhibits collective invasion in 3-D
culture
The highly metastatic mouse mammary tumor 4T1
cell line expresses significant amounts of endogenous
podocalyxin compared with genetically similar mammary
tumor cell lines that are either weakly metastatic (66 cl4)
or nonmetastatic (67NR; Fig. 7a). Despite their high meta-
static potential, 4T1 cells form epithelial E-cadherin-
containing adherens junctions [42]. We thus reasoned that
these cells were good candidates to be collectively invasive
in 3-D culture, which turned out to be the case. Specific-
ally, when we preclustered 4T1-control cells and overlaid
them with collagen type 1, the clusters sent out collective,
bud-like protrusions into the matrix that contained
polarity-disrupted aggregations of podocalyxin, some of
which appeared to be associated with microlumenal struc-
tures (Fig. 7c, left panels; Additional file 3: Movie S3). In
contrast, when we stably knocked down podocalyxin,
the resulting 4T1-podo KD 3603 cells (Fig. 7b) did not
productively invade the matrix as cohesive cell cohorts.
Instead, a small proportion of 4T1-podo KD cells moved
into the gel singly in an elongated fashion (Fig. 7c, right
panels, arrowheads; Additional file 3: Movie S4).
Discussion
Podocalyxin was initially described as the major glom-
erular anion in the kidney that plays a critical role in the
formation of the small gaps between the individual pro-
cesses of podocytes that become the slit diaphragms
which are critical for plasma filtration during the initial
phase of urine formation [14]. This was confirmed in
podocalyxin knockout mice where the glomerular epi-
thelium remains patent and no filtration occurs [15].
Podocalyxin was later shown to be gp135, which had
long been used as a marker of the apical membrane
domain of MDCK kidney epithelial cells in 2-D mono-
layer culture [16]. Functional experiments in MDCK
cells demonstrated that podocalyxin contributes to the
formation of a preapical membrane domain during the
formation of a single central lumen within polarized
MDCK cell spheroids maintained in 3-D collagen gels
[16]. Interestingly, when apical–basal polarity is actively
disrupted by blocking integrin function, podocalyxin is
not trafficked properly, a single central lumen does not
form efficiently, and the otherwise normal MDCK epi-
thelial cell spheroids start to move collectively through
the collagen matrix [19].
When we force-expressed podocalyxin in normal
mammary epithelial cells and placed the cells in 3-D cul-
ture, they clustered together and, similar to MDCK cells,
formed polarized spheroids with a large, single lumen
that was centrally located (Additional file 1: Figure S3).
In contrast, epithelial MCF-7 breast tumor cells have an
intrinsic polarity defect such that control MCF-7 spher-
oids did not generate a single central lumen. Instead, as
demonstrated by Muc1 staining, the control MCF-7 cell
clusters formed multiple small internal apical membrane
domains. Forced podocalyxin overexpression in MCF-7
cells served to facilitate the expansion and separation of
these domains during microlumen formation within
elongating MCF-7-podo cell clusters that began to pro-
trude collectively into the ECM. Therefore, the intrinsic
polarity defect in the MCF-7 spheroids, which has been
shown to be mediated, at least in part, by aberrant integ-
rin signaling [41], may have contributed to the ability of
podocalyxin to initiate their collective invasion in a fash-
ion analogous to that which occurred in integrin-
blocked MDCK cell spheroids [19].
In MDCK cells, the movement of podocalyxin to ap-
ical and luminal membrane domains that occurs during
the normal polarization process is dependent on the
interaction of its cytoplasmic domain with the actin
scaffolding proteins ezrin, NHERF-1, and NHERF-2 [19].
We showed here that ezrin colocalized with podocalyxin
at the microlumenal membranes of collectively invasive
MCF-7 cell aggregates, and we have shown previously
that NHERF-1 also colocalizes with podocalyxin in these
cells in small punctate microvillus-like structures when
they are maintained in 2-D monolayer culture [34].
Mostov and colleagues have suggested that an inappro-
priate targeting of podocalyxin and these associated scaf-
folding proteins contributes to the formation of leading
lamella-like structures that drive collective MDCK cell
invasion under polarity-disrupted conditions in 3-D cul-
ture [19]. We found that force-expressed apical podoca-
lyxin localized directly adjacent to expanded actin-rich
lamella at the free edge of collective migrating MCF-7
monolayers in 2-D culture. Importantly, when we treated
these cells with a pharmacologic inhibitor of ezrin
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activation, we observed a disruption of ezrin and podoca-
lyxin localization in the apical domain of these cells and a
decrease in collective migration which broadly agrees with
the findings of Mostov and colleagues who used normal
epithelial cells where polarity was actively disrupted in
3-D culture to initiate an ezrin-dependent podocalyxin-
mediated collective invasion [19].
We also found that podocalyxin overexpression stimu-
lated the formation of actin-rich lamellipodia-like
protrusions that emanated from the collectively invad-
ing MCF-7-podo cell aggregates in 3-D culture. Thus,
podocalyxin likely acts in subtly different ways from
podoplanin, which is another small mucin that initiates
collective tumor cell motility by inducing the formation of
filopodial rather than lamella-like structures [43]. Regard-
less, the ability of polarity-disrupted podocalyxin to initi-
ate the formation of cellular processes that protrude into
the matrix is likely critical for facilitating collective
Fig. 7 Stable knockdown of podocalyxin in highly invasive 4T1 murine breast tumor cells reduces collective invasion. a Whole cell lysates from syngeneic
murine breast tumor cell lines with different capacities to metastasize were probed for endogenous podocalyxin expression. Endogenous podocalyxin was
most highly expressed in 4T1 cells, which are highly metastatic compared with the nonmetastatic 67NR and weakly metastatic 66 cl4 cell lines
[42]. b 4T1 cells stably transfected with either control vector (4T1-control) or vectors containing an shRNA sequence targeting the 3′ untranslated region of
the murine podocalyxin transcript were analyzed for endogenous podocalyxin expression by western blotting. Stable 4T1 cell populations, each expressing
a different short hairpin sequence, show a moderate (podo KD-3293) and near complete knockdown of endogenous podocalyxin (podo KD-3603),
respectively. c 4T1-control or 4T1-podo KD 3603 tumor cells were aggregated on Matrigel overnight, overlaid with collagen type I, and maintained in
3-D culture for 4 days. They were then imaged, live, by phase microscopy (upper panels) or fixed and immunostained for endogenous podocalyxin
(red) and the tight junction protein ZO-1 (green) followed by confocal imaging (lower panels). The 4T1-control cells invaded as cohesive multicellular
strands with scattered small pockets of poorly polarized podocalyxin throughout. In contrast, aggregates from podocalyxin knockdown cells did not
effectively invade as cohesive multicellular strands; they did, however, occasionally release single cells into the matrix (arrowheads). Scale = 50 μm
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invasion because such processes are prominent in “leader”
[11] and “trailblazer” [12] cells that drive collective inva-
sion by heterogeneous breast cancer cell populations.
Additionally, as is the case with leader and trailblazer
cell-driven collective invasion, MCF-7-podo cells only
generated these processes and became collectively in-
vasive when stromal collagen (type I) was added to the
3-D culture system (i.e., they did not form processes and
they were not invasive in Matrigel-only 3-D cultures;
data not shown).
Podocalyxin has been shown to activate the actin
nucleator cortactin in a NHERF-1-dependent manner
[44]. This activation may also contribute to podocalyxin’s
ability to initiate leading lamellipodial protrusions under
conditions that favor collective cell motility. Addition-
ally, podocalyxin-mediated alterations in NHERF protein
localization may act to augment growth factor-mediated
signaling that contributes to the collective motile
phenotype given the ability of NHERF proteins to
interact with multiple hormone and growth factor recep-
tors [45]. Indeed, we found that podocalyxin overexpres-
sion increased EGF-dependent mitogen-activated protein
kinase and phosphoinositide 3-kinase-dependent signaling
in MCF-7 cells (Additional file 1: Figure S5). We are now
manipulating the interactions of NHERF-1 (MCF-7 cells
do not express appreciable amounts of NHERF-2) with
the cytoplasmic tail of podocalyxin to determine
which of these interactions influences EGF-dependent
signaling, lamellipodial protrusion, and/or collective mo-
tility in the presence or absence of ezrin. Finally, the heav-
ily glycosylated extracellular domain of podocalyxin could
act to augment a glycocalyx-mediated stimulation of
integrin-dependent signaling to further facilitate epithelial
tumor cell motility [46].
A polarity protein that is linked to the cytoskeleton,
podocalyxin may modulate subcellular asymmetries in
cytoskeletal contractility that have also been shown to
contribute to experimental collective cell motility [10].
In accordance with this, it has been demonstrated that
podocalyxin augments contractile RhoA activation at the
free surface of kidney epithelial cells in an ezrin-
dependent manner [47, 48] and we have shown that
podocalyxin-induced collective invasion is dependent on
acto-myosin contractility. Sahai and colleagues have
demonstrated that the Par3 and Par6 polarity proteins
generate contractile asymmetries in collectively migrat-
ing squamous carcinoma cells through their interaction
with the collagen-binding Discoidin Domain Receptor 1
(DDR1) [49]. Interestingly, the expression of DDR1 helps
to clinically distinguish invasive ductal breast carcinomas,
which are often cohesive and epithelial, from invasive
lobular breast carcinoma which often generate mesenchy-
mal cells that move through the stromal matrix in a
“single file” arrangement [50]. It is intriguing to consider
the possibility that podocalyxin and DDR1 may be
mechanistically linked given that their expression is
coordinately suppressed by miR-199b-5p, a microRNA
whose loss leads to the elevation of both DDR1 and
podocalyxin in acute myeloid leukemia [51].
Tumor budding, which is regarded to be an important
component of local tumor cell dissemination, has signifi-
cant prognostic significance in a number of solid tumor
types, including breast cancer [6–8]. By the strictest def-
inition, tumor buds are small (i.e., less than five cells
[9]). Interestingly, however, larger invasive cell clusters
and micronodules can have as great, or greater, prognos-
tic significance. The latter structures, which can consist
of dozens of cells, have been classified as “poorly differ-
entiated clusters” (PDCs) in invasive breast cancer given
that their polarity is often disrupted such that they do
not contain single, well-defined central lumens [8]. Based
on morphology, size, and lack of a single central lumen, it
would appear that the collectively invasive cell clusters
that we observed in MCF-7-podo cell xenotransplants
more closely resemble clinical PDCs. Whether or not
increases in proliferation rates play a role in this budding
is not clear clinically [7–9], and while proliferating
cells were present in the budding clusters of MCF-7-
podo cells in the xenotransplants, any proliferative
differences with control tumors were, at best, minimal.
Thus, it is unlikely that proliferation is a major driver
of podocalyxin-mediated collective invasion in vivo.
Additionally, differences in proliferation rates were not a
factor in the increased collective motility of the MCF-7-
podo cells in culture.
Like smaller tumor buds, the presence of PDCs is well
correlated with LVI which is another prognostic indica-
tor of progression in invasive breast cancer [8]. Initially,
we found that podocalyxin overexpression is also a prog-
nostic indicator of poor outcome, overall, in invasive
breast cancer [13]. This was later confirmed by Andrulis
and colleagues, who demonstrated that podocalyxin
overexpression is also positively correlated with LVI
amongst an entire invasive breast cancer cohort [31].
Interestingly, however, Andrulis’ group also found that
podocalyxin overexpression was negatively correlated
with outcome within the LVI breast cancer subco-
hort itself. This suggests to us that podocalyxin may
contribute to an initial local dissemination via collect-
ive tumor invasion but that a subsequent retention of
podocalyxin could suppress a later more aggressive
spread by helping to prevent, for example, a switch
from a collective to a more mesenchymal mode of inva-
sion. Given this, it will be interesting to determine
whether endogenous podocalyxin contributes to the
tightly regulated collective invasion that helps to drive
branching morphogenesis during normal mammary
gland development [52].
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There is one report that podocalyxin facilitates a trans-
forming growth factor beta-mediated mesenchymal trans-
formation of A549 lung carcinoma cells [53]. However, we
found that podocalyxin overexpression did not prevent
cell–cell junction formation or downregulate epithelial
marker expression in MCF-7 cells. We also force-
expressed podocalyxin in epithelial ovarian carcinoma
cells [30] and saw no evidence that this leads to the
emergence of an overt mesenchymal phenotype on its
own. However, we have not fully investigated the possibil-
ity that podocalyxin upregulates selected mesenchymal
markers within otherwise epithelial tumor cells which
have been shown to be a part of the collectively invasive
breast tumor budding phenotype [9, 12]. Interestingly,
when we knocked down endogenous podocalyxin in
highly metastatic, but still epithelial, 4T1 mammary tumor
cells, while there was a clear decrease in collective inva-
sion there was also an increase in the movement of single
elongated cells into the matrix. Thus, it is possible that a
late-stage loss of podocalyxin may stimulate a shift to-
wards a single cell mode of motility which could be associ-
ated with the emergence of a mesenchymal phenotype.
Under some conditions, such a mode shift could poten-
tially lead to the emergence of a more aggressive pheno-
type, a notion that is supported by the clinical data of
Andrulis and colleagues already described [31]. Whether
or not the loss of podocalyxin can initiate a switch be-
tween collective and mesenchymal modes of tumor cell
invasion is something we are actively investigating.
In addition to invasive breast cancer, podocalyxin over-
expression is also correlated with poor outcome in other
epithelial-derived cancers where alterations in polarity
figure prominently in tumor formation and progression.
These include renal cell, colorectal, high-grade serous
ovarian, and bladder carcinomas [28–30, 32, 33]. In the
latter case, increased podocalyxin levels are also predictive
of outcome [33]. Given these findings, we developed anti-
bodies against the podocalyxin extracellular domain in an
effort to block its tumor progression promoting function.
Our initial studies indicate that this is feasible in preclin-
ical transplantation experiments using metastatic breast
and mammary tumor cell lines that overexpress podo-
calyxin [54]. Therefore, podocalyxin overexpression may
represent a novel therapeutic target in metastatic carcin-
oma progression.
Conclusions
Podocalyxin overexpression causes epithelial tumor cells
to become collectively motile in culture and to initiate
collectively invasive tumor budding in orthotopic trans-
plants in vivo. Therefore, in addition to being prognos-
tically significant for breast cancer outcome, podocalyxin
overexpression may functionally contribute to breast
cancer progression.
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